• Leukemia & Lymphoma Society of Canada Raises $6 Million for Blood Cancer Research
  • Takeda to Showcase Adcetris as First-line Therapy in Hodgkin’s Lymphoma at ASH Meeting
  • EMA Urges European Commission to Approve Takeda’s Adcetris as Therapy for CTCL
  • Potential Treatment for Advanced CTCL, Mogamulizumab, Under Review in Europe
  • FDA Approves Adcetris for Most Common Subtypes of Cutaneous T-cell Lymphoma
  • Seattle Genetics Asks FDA to Accept Adcetris as Treatment for Hodgkin’s Lymphoma
  • Novartis Files for Approval of Kymriah for Two Blood Cancers in the EU
  • Study Links Early Progression to Poorer Survival Outcomes in Follicular Lymphoma Patients
  • Bayer to Present Long-term Results of Aliqopa in Treating Indolent Lymphomas at ASH 2017
  • MorphoSys’ MOR208 Receives Breakthrough Therapy Status in US for Relapsed or Refractory DLBCL
  • Novartis Asks FDA to Approve Kymriah for Difficult-to-treat DLBCL
  • FDA Grants Accelerated Approval to Calquence for Mantle Cell Lymphoma